SVB Leerink Starts Rapt Therapeutics (RAPT) at Outperform

SVB Leerink analyst Thomas Smith initiates coverage on Rapt Therapeutics (NASDAQ: RAPT) with a Outperform rating and a price target of $49.00.

For an analyst ratings summary and ratings history on Rapt Therapeutics click here. For more ratings news on Rapt Therapeutics click here.

Shares of Rapt Therapeutics closed at $33.07 yesterday.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• BofA Securities Resumes Williams-Sonoma (WSM) at Buy
• CMB International Securities Starts Lumentum (LITE) at Buy